Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -8.84% is 200% below its 3-year average of 8.88%, near the low end of its 3-year range (-8.84%–29.30%).
As of the fiscal period ended Tuesday, March 31, 2026. 93.65% below its 12-month average of -4.56%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-03-31): -10.04%.
RETURN ON ASSETS (ROA)
-8.84%
RETURN ON ASSETS (ROA) AVG TTM
-4.56%
RETURN ON ASSETS (ROA) AVG 3Y
8.88%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-93.65%
CURRENT VS 3Y AVG
-199.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+72.60%
vs the sector median at left
Cellyan Biotechnology Co., Ltd
Market Cap
$1.13M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
N/A
Market Cap
$1.12M
Return on Assets (ROA)
-147.60%
TTM Avg
-223.87%
3Y Avg
-1843.76%
5Y Avg
-4349.14%
Market Cap
$1.17M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$1.08M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.01M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$946332.00
Return on Assets (ROA)
-17.34%
TTM Avg
-18.34%
3Y Avg
-35.92%
5Y Avg
-162.42%
Market Cap
$1.32M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
Market Cap
$1.33M
Return on Assets (ROA)
-72.52%
TTM Avg
-80.61%
3Y Avg
-249.55%
5Y Avg
-240.26%
Market Cap
$1.34M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.13M | -8.84% | -4.56% | 8.88% | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | -147.60% | -223.87% | -1843.76% | -4349.14% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -64.99% | -31.34% | -98.36% | -79.15% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -44.32% | -57.72% | -286.30% | -215.47% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | -17.34% | -18.34% | -35.92% | -162.42% |
| Genprex, Inc. (GNPX)vs › | $1.32M | -96.27% | -335.81% | -263.87% | -193.48% |
| NewcelX Ltd. (NCEL)vs › | $1.33M | -72.52% | -80.61% | -249.55% | -240.26% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | -196.18% | -334.48% | -197.38% | -169.68% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
ROA
-8.8%
ROE
-11.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -8.84% |
| 2025-03-31 | -0.29% |
| 2024-03-31 | 15.34% |
| 2023-03-31 | 29.30% |
